Prior to Iomai, he served as president and CEO of Procept, a publicly traded immunology company, as vice president, corporate development at Integrated Genetics (now Genzyme), and in management positions within Baxter International.
Mr Erck received his undergraduate degree from the University of Illinois and his MBA from the University of Chicago Graduate School of Business.
Jon Stonehouse, president and CEO of BioCryst Pharmaceuticals, said: “We are pleased to welcome Mr Erck to our board of directors. Stan’s experience in leading biotech companies and his knowledge of managing a large advanced development contract from the Department of Health and Human Services will be of great value to BioCryst as the company advances its clinical pipeline.”